New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamotrigine 50mg - chewable/dispersible tablet - 50 mg - active: lamotrigine 50mg excipient: aluminium magnesium silicate blackcurrant flavour 502009 ap0551 calcium carbonate hyprolose magnesium stearate povidone saccharin sodium sodium starch glycolate - epilepsy adults (over 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - lamotrigine - dispersible tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - lamotrigine - dispersible tablet - 2mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline pharmaceuticals s.a. - lamotrigine - tablets chewable/dispersible - 5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamotrigine, quantity: 50 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; silicon dioxide; saccharin sodium; mannitol; magnesium stearate; flavour - lamotrigine is an anti-epileptic drug used for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamotrigine, quantity: 200 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; silicon dioxide; saccharin sodium; mannitol; magnesium stearate; flavour - lamotrigine is an anti-epileptic drug used for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamotrigine, quantity: 100 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; silicon dioxide; saccharin sodium; mannitol; magnesium stearate; flavour - lamotrigine is an anti-epileptic drug used for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 25 mg - tablet - excipient ingredients: calcium carbonate; hyprolose; aluminium magnesium silicate; sodium starch glycollate; povidone; saccharin sodium; magnesium stearate; flavour - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as ?add-on? therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - lamotrigine - dispersible tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - lamotrigine - dispersible tablet - 25mg